Plasma components: properties, differences, and uses

Benjamin, Richard J.; McLaughlin, Lisa Swinton

doi:10.1111/j.1537-2995.2012.03622.x

Cited by 112 publications

(105 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Compared to studies that used PCC to reverse warfarin anticoagulation, FIBC studies more commonly involved conflicts of interest and industry funding. With these latter studies, the sample size in the prospective arms was generally small (mean, 12; range, [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22]; and the historical comparator cohorts were not well matched to the intervention arm groups. Therefore, with the exception of randomized controlled trials by Karlsson and colleagues (2009) [10] and Fenger-Eriksen and colleagues (2009) [18], most studies were assessed to have a high degree of methodological bias.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Use of Prothrombin Complex Concentrates and Fibrinogen Concentrates in the Perioperative Setting: A Systematic Review

Lin

Murphy

Tran

2013

Transfusion Medicine Reviews

View full text Add to dashboard Cite

The use of prothrombin complex concentrates (PCCs) and fibrinogen concentrates (FIBCs) to achieve hemostasis in the perioperative setting as alternatives to allogeneic blood products remains controversial. To examine the efficacy and safety of PCCs and FIBCs, we conducted a systematic review-in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement-to compare the use of these transfusion alternatives in bleeding surgical patients. We performed a literature search of English articles published between July 1997 and July 2012 in MEDLINE via PubMed, The Cochrane Library, and CINAHL. Five randomized trials and 15 nonrandomized studies with a comparator group were included in the final review. Studies were sorted into 1 of the following 3 clinical settings: cardiac surgery, non-cardiac surgery, and reversal of warfarin anticoagulation. Risk of bias was assessed using the Cochrane risk of bias tool. With the exception of 2 randomized controlled trials, the existing body of literature on the use of PCCs and FIBCs in the perioperative setting was assessed to have a high degree of methodological bias. Overall, prospective studies in the cardiac surgery grouping suggested that patients receiving FIBC and/or PCCs required less allogeneic blood transfusion and had less chest tube drainage. In studies of warfarin reversal, PCCs more rapidly corrected the International Normalized Ratio compared to plasma; however, in the setting of intracranial hemorrhage, functional outcomes were poor regardless of the reversal strategy. With regards to safety outcomes, reporting was not uniform and raises concerns of underreporting. Adequately powered, methodologically sound trials would be required for more definitive conclusions to be drawn about the efficacy of PCCs and FIBC over conventional blood components for the treatment of perioperative coagulopathy in bleeding patients.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Administering fresh frozen plasma (FFP) in patients with minimally elevated International Normalized Ratio (INR) values has been shown to be ineffective in producing meaningful corrections [4,5]. Commonly recommended doses vary between 10 and 30 mL/kg [6,7]. At these therapeutic doses, a 70-kg patient might receive between 700 and 2100 mL of plasma.…”

mentioning

confidence: 99%

Use of Prothrombin Complex Concentrates and Fibrinogen Concentrates in the Perioperative Setting: A Systematic Review

Lin

Murphy

Tran

2013

Transfusion Medicine Reviews

View full text Add to dashboard Cite

show abstract

“…The detailed analyses are part of the approval by the regulatory authorities and have been published in several key reviewed publications [16]. [34] One question was concerning a potential generation of reactive oxygen species (ROS) during the INTERCEPT process. In contrast to other technologies, the generation of ROS is not an integral part of the mechanism of action for INTERCEPT and only minor amounts are generated [7,[14][15][16][17].…”

Section: Discussionmentioning

confidence: 99%

“…The transmission of pathogens via the transfusion of labile blood components is an ongoing threat [33,34]. On the one hand donor selection and development of testing systems has significantly lowered that risk.…”

Section: Discussionmentioning

confidence: 99%

Update on pathogen inactivation treatment of plasma, with the INTERCEPT Blood System: Current position on methodological, clinical and regulatory aspects

Irsch¹,

Seghatchian

2015

Transfusion and Apheresis Science

View full text Add to dashboard Cite

“…While much has been written in the transfusion medicine journals on plasma and platelet apheresis, the typical focus has been on the physiological effects of donating [41,42]. For BCAs operating in voluntary, non-remunerated contexts, there is no established literature on what motivates donors to become and remain plasma and/or platelet donors.…”

Section: Research Focus - Initiating and Maintaining Plasma Donationmentioning

confidence: 99%

Donor Research in Australia: Challenges and Promise

Masser

Smith

Williams

2014

Transfus Med Hemother

View full text Add to dashboard Cite

Donors are the key to the core business of Blood Collection Agencies (BCAs). However, historically, they have not been a focus of research undertaken by these organizations. This model is now changing, with significant donor research groups established in a number of countries, including Australia. Donor research in the Australian Red Cross Blood Service (Blood Service) is concentrated in the Donor and Community Research (DCR) team. Cognizant of the complex and ever-changing landscape with regard to optimal donor management, the DCR team collaborates with academics located at universities around Australia to coordinate a broad program of research that addresses both short- and-long term challenges to the blood supply. This type of collaboration is not, however, without challenges. Two major collaborative programs of the Blood Service's research, focusing on i) the recruitment and retention of plasmapheresis donors and ii) the role of the emotion pride in donor motivation and return, are showcased to elucidate how the challenges of conducting collaborative BCA research can be met. In so doing, these and the other research programs described herein demonstrate how the Blood Service supports and contributes to research that not only revises operational procedures but also contributes to advances in basic science.

show abstract

Plasma components: properties, differences, and uses

Cited by 112 publications

References 63 publications

Use of Prothrombin Complex Concentrates and Fibrinogen Concentrates in the Perioperative Setting: A Systematic Review

Use of Prothrombin Complex Concentrates and Fibrinogen Concentrates in the Perioperative Setting: A Systematic Review

Update on pathogen inactivation treatment of plasma, with the INTERCEPT Blood System: Current position on methodological, clinical and regulatory aspects

Donor Research in Australia: Challenges and Promise

Contact Info

Product

Resources

About